The signing of an agreement with a Californian medical group
is further confirmation Pacific Edge Ltd is ''moving
forward'' in the United States, Craigs Investment Partners
broker Peter McIntyre says.
The Dunedin-based cancer-diagnostic company's agreement with
the Southern California Permanente Medical Group is to
research its user programme to evaluate its bladder cancer
technology, Cxbladder, within the clinical settings of Kaiser
Permanente's health care network.
It was planned to recruit about 2000 patients presenting with
blood in the urine from the 3.7 million members of Kaiser
Permanente Southern California.
The user programme research was scheduled to begin later this
year and be completed in early 2015.
User programmes were a key part of the adoption process,
allowing customers to obtain data and experience the benefits
of using the Cxbladder technology in their own clinical
settings, Pacific Edge chief executive David Darling said.
With its provision of services to 9.5 million people, Kaiser
Permanente cared for a population twice the size of all of
New Zealand's district health boards.
Mr McIntyre said it was all about Pacific Edge's ability to
adapt to increased demand, given the ''massive'' population